Tellgen Corporation's Subsidiaries Obtain Regulatory Approvals for Two Diagnostic Products

Stock News
2 hours ago

Tellgen Corporation (300642.SZ) has officially announced that its controlling subsidiaries, Jiangxi Tellgen Life Science Technology Co., Ltd. and Shanghai Maishi Biotechnology Co., Ltd., have recently secured medical device registration certificates from the Jiangxi Medical Products Administration and the Shanghai Medical Products Administration, respectively.

The newly approved products include the fully automated flow fluorescence luminescence immunoassay analyzer, available in models TESMIF5000 and TESMIF5000M, as well as a four-item anti-epileptic drug concentration assay kit utilizing liquid chromatography-tandem mass spectrometry methodology.

These regulatory clearances mark a significant milestone for the company's subsidiaries, expanding their product portfolios in the in-vitro diagnostics sector and reinforcing their market presence across the region.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10